OptimizeRx Co. (NASDAQ:OPRX) Receives Average Recommendation of “Moderate Buy” from Analysts

OptimizeRx Co. (NASDAQ:OPRX) has been given a consensus rating of “Moderate Buy” by the nine analysts that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $9.06.

A number of brokerages have weighed in on OPRX. Stephens began coverage on shares of OptimizeRx in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.50 target price for the company. Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 target price on shares of OptimizeRx in a research note on Tuesday, December 24th. Roth Mkm reaffirmed a “buy” rating and issued a $16.00 target price (down from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. B. Riley dropped their target price on shares of OptimizeRx from $17.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, December 24th. Finally, Barclays dropped their price target on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, November 14th.

OptimizeRx Trading Up 0.8 %

Shares of NASDAQ OPRX opened at $5.18 on Friday. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $16.65. The company has a market cap of $95.42 million, a PE ratio of -3.89 and a beta of 1.38. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The company has a 50-day moving average of $5.46 and a two-hundred day moving average of $6.14.

Insider Buying and Selling

In other news, CEO William J. Febbo acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the acquisition, the chief executive officer now owns 601,253 shares in the company, valued at $3,012,277.53. This trade represents a 3.44 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 6.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of OPRX. SBI Securities Co. Ltd. acquired a new position in OptimizeRx during the fourth quarter valued at approximately $25,000. BNP Paribas Financial Markets boosted its holdings in shares of OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after buying an additional 2,414 shares during the period. SG Americas Securities LLC acquired a new position in shares of OptimizeRx in the fourth quarter valued at approximately $51,000. Wells Fargo & Company MN boosted its holdings in shares of OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock valued at $54,000 after buying an additional 2,797 shares during the period. Finally, Quest Partners LLC boosted its holdings in shares of OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after buying an additional 9,739 shares during the period. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.